Plain-English translation of NCT06349889 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy medication called combined with chemotherapy and radiation therapy for people with advanced nasopharyngeal cancer (cancer of the upper throat behind the nose). The medication works by helping your immune system fight cancer cells. Researchers want to see if adding this treatment to the standard approach improves survival and outcomes.
Nasopharyngeal cancer is often diagnosed at an advanced stage, and current treatments don't work well enough for everyone. This trial is exploring whether the medication can boost the effectiveness of chemotherapy and radiation to help more patients survive and recover.
You likely qualify if…
You likely don't qualify if…
You would receive three cycles of chemotherapy (two drugs given intravenously every three weeks) before starting radiation therapy. During radiation (about 6–7 weeks), you would receive additional chemotherapy and the new medication intravenously every three weeks. After radiation ends, you would continue receiving the medication alone for nine more cycles (about 6 months). Throughout, you would have regular blood tests and imaging scans to monitor your response and watch for side effects.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China